The fatigue and breathlessness program specific to interstitial lung disease is feasible, acceptable, and clinically effective.
Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- ...
Despite data gaps in many countries, the burden of sickle cell disease, especially in west and central Africa, underscores ...
Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results